{"doc_id": "33279317", "type of study": "Therapy", "title": "", "abstract": "Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.\nPassive surveillance is recommended globally for the detection of adverse events following immunisation (AEFI) but this has significant challenges.\nUse of Mobile health for vaccine safety surveillance enables a consumer-centred approach to reporting.\nThe Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) a randomised control trial (RCT) sought to evaluate the efficacy and acceptability of SMS for AEFI surveillance.\nMulti-centre RCT, participants were adult vaccinees or parents of children receiving any vaccine at a trial site.\nAt enrolment randomisation occurred to one of two SMS groups or a control group.\nPrompts on days 2, 7 and 14 post-immunisation, were sent to the SMS group, to ascertain if a medical event following immunisation (MEFI) had occurred.\nNo SMS's were sent to the control participants.\nThose in the SMS who notified an MEFI were pre-randomised to complete a computer assisted telephone interview or a web based report to determine if an AEFI had occurred whilst an AEFI in the controls was determined by a search for passive reports.\nThe primary outcome was the AEFI detection rate in the SMS group compared to controls.\nWe enrolled 6,338 participants, who were equally distributed across groups and who received 11,675 vaccines.\nThe SMS group (4,225) received 12,675 surveillance prompts with 9.8% being non-compliant and not responding.\nIn those that responded 90% indicated that no MEFI had been experienced and 184 had a verified AEFI.\n6 control subjects had a reported AEFI.\nThe AEFI detection rate was 13 fold greater in the SMS group when compared with controls (4.3 vs 0.3%).\nWe have demonstrated that the STARSS methodology improves AEFI detection.\nOur findings should inform the wider use of SMS-based surveillance which is particularly relevant since establishing robust and novel pharmacovigilance systems is critical to monitoring novel vaccines which includes potential COVID vaccines.\nCrown Copyright \u00a9 2020. Published by Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "immunization", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 79}, {"term": "adult vaccinees", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 52}, {"term": "parents of children receiving any vaccine", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 97}, {"term": "immunisation", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 46}, {"term": "MEFI", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 37}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance ( STARSS ) randomised control trial .", "Evidence Elements": {"Participant": [{"term": "immunization", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 79}], "Intervention": [{"term": "m-Health", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 20}], "Outcome": [{"term": "detection of adverse events", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 56}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Passive surveillance is recommended globally for the detection of adverse events following immunisation ( AEFI ) but this has significant challenges .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Use of Mobile health for vaccine safety surveillance enables a consumer-centred approach to reporting .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "The Stimulated Telephone Assisted Rapid Safety Surveillance ( STARSS ) a randomised control trial ( RCT ) sought to evaluate the efficacy and acceptability of SMS for AEFI surveillance .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 137}, {"term": "acceptability", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 155}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Multi-centre RCT , participants were adult vaccinees or parents of children receiving any vaccine at a trial site .", "Evidence Elements": {"Participant": [{"term": "adult vaccinees", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 52}, {"term": "parents of children receiving any vaccine", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 97}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "At enrolment randomisation occurred to one of two SMS groups or a control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SMS", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 53}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 73}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Prompts on days 2 , 7 and 14 post-immunisation , were sent to the SMS group , to ascertain if a medical event following immunisation ( MEFI ) had occurred .", "Evidence Elements": {"Participant": [{"term": "immunisation", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 46}], "Intervention": [{"term": "SMS", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 69}], "Outcome": [{"term": "medical event", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 109}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "No SMS 's were sent to the control participants .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "negated", "UMLS": {}, "start": 27, "end": 34}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Those in the SMS who notified an MEFI were pre-randomised to complete a computer assisted telephone interview or a web based report to determine if an AEFI had occurred whilst an AEFI in the controls was determined by a search for passive reports .", "Evidence Elements": {"Participant": [{"term": "MEFI", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 37}], "Intervention": [{"term": "controls", "negation": "affirmed", "UMLS": {}, "start": 191, "end": 199}], "Outcome": [{"term": "AEFI", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 155}, {"term": "AEFI", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 155}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was the AEFI detection rate in the SMS group compared to controls .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SMS", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 58}, {"term": "controls", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 85}], "Outcome": [{"term": "AEFI detection rate", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 47}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "We enrolled 6,338 participants , who were equally distributed across groups and who received 11,675 vaccines .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The SMS group ( 4,225 ) received 12,675 surveillance prompts with 9.8 % being non-compliant and not responding .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SMS", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 7}], "Outcome": [{"term": "surveillance prompts", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 60}, {"term": "non-compliant", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 91}], "Observation": [{"term": "12,675", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 39}], "Count": [{"term": "9.8 %", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 71}]}, "Evidence Propositions": [{"Intervention": "SMS", "Observation": "", "Count": "9.8 %", "Outcome": "non-compliant"}]}, {"Section": "RESULTS", "Text": "In those that responded 90 % indicated that no MEFI had been experienced and 184 had a verified AEFI .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "MEFI", "negation": "negated", "UMLS": {}, "start": 47, "end": 51}, {"term": "verified", "negation": "negated", "UMLS": {}, "start": 87, "end": 95}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "6 control subjects had a reported AEFI .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 9}], "Outcome": [{"term": "AEFI", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 38}], "Observation": [], "Count": [{"term": "6", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 1}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The AEFI detection rate was 13 fold greater in the SMS group when compared with controls ( 4.3 vs 0.3 % ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SMS", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 54}, {"term": "controls", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 88}], "Outcome": [{"term": "AEFI detection rate", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 23}], "Observation": [{"term": "13 fold greater", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 43}, {"term": "4.3", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 94}], "Count": []}, "Evidence Propositions": [{"Intervention": ["SMS", "controls"], "Observation": "13 fold greater", "Outcome": "AEFI detection rate", "Count": ""}, {"Intervention": "SMS", "Observation": "4.3", "Outcome": "AEFI detection rate", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "We have demonstrated that the STARSS methodology improves AEFI detection .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "STARSS methodology", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 48}], "Outcome": [{"term": "AEFI detection", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 72}], "Observation": [{"term": "improves", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 57}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Our findings should inform the wider use of SMS-based surveillance which is particularly relevant since establishing robust and novel pharmacovigilance systems is critical to monitoring novel vaccines which includes potential COVID vaccines .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Crown Copyright \u00a9 2020 . Published by Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}